NASDAQ:BLUE
bluebird bio Stock News
$1.03
-0.0200 (-1.90%)
At Close: May 17, 2024
BMS & bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients
Bristol-Myers, Bluebird Bio to Resubmit FDA Bid for Myeloma Treatment
02:41pm, Wednesday, 13'th May 2020
Bristol-Myers Squibb and Bluebird Bio say the FDA declined to move forward on the application for their experimental multiple myeloma treatment.
20 Healthcare Stocks Moving In Wednesday's Pre-Market Session
11:33am, Wednesday, 13'th May 2020
BMS and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
12:00am, Wednesday, 13'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
U.S. RESEARCH ROUNDUP-Digital Realty Trust, Pilgrims Pride, Terraform Power
07:26am, Tuesday, 12'th May 2020
Wall Street securities analysts revised their ratings and price targets on
several U.S.-listed companies, including Digital Realty Trust, Pilgrims Pride and Terraform Power,
on Tuesday.
HIGH
BMO Capital Maintains Outperform on bluebird bio, Raises Price Target to $112
12:00am, Tuesday, 12'th May 2020Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
04:01pm, Monday, 11'th May 2020
The pharma giant and the smaller biotech will keep working together on a couple of promising CAR-T cancer therapies.
Bristol Myers to pay bluebird $200 million for future royalties on cancer therapies
03:22pm, Monday, 11'th May 2020
The treatments, ide-cel and bb21217, are part of a class of drugs called CAR-T therapies that involve drawing white blood cells from a patient, processing them to target cancer cells, and infusing the
Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates
12:25pm, Monday, 11'th May 2020
Bluebird (BLUE) delivered earnings and revenue surprises of 7.61% and 147.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement
11:35am, Monday, 11'th May 2020
bluebird bio, Inc. (NASDAQ: BLUE) today announced that it has amended its existing co-promotion/co-development agreement with Bristol Myers Squibb (BMS) to enable the companies to focus their efforts
bluebird bio Provides Operational and Business Update and Reports First Quarter 2020 Financial Results
11:00am, Monday, 11'th May 2020
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2020 and provided an operational update.
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
Is a Surprise Coming for bluebird bio (BLUE) This Earnings Season?
01:55pm, Friday, 08'th May 2020
bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
